ERBB2 and breast carcinoma: About 29% of breast cancers and roughly 40% of hormone receptor positive/human epidermal receptor 2 negative (HR + /HER2-) metastatic breast cancers exhibit abnormal Phosphatidylinositol 3-kinase catalytic 110-KD alpha (PI3K-α) signaling [2].